Sibylle Loibl, Chief Executive Officer at the German Breast Group Research Company (GBG Forschungs GmbH), shared a post on LinkedIn:
“Publication in the NEJM: Important data for HR+/ HER2+ metastatic breast cancer
The phase 3 PATINA trial (NCT02947685, GBG94, AFT38), now published in The New England Journal of Medicine, presents practice-changing results for patients with hormone receptor–positive, HER2-positive metastatic breast cancer.
Study concept
The trial evaluated whether adding palbociclib to maintenance therapy (anti-HER2 plus endocrine therapy) after initial chemotherapy provides additional benefit.
Key findings
Significant improvement in progression-free survival (PFS): 44.3 months vs. 29.1 months (HR for disease progression or death 0.75; two-sided p = 0.02). As expected, higher rates of grade 3/4 adverse events, predominantly neutropenia.
Conclusion
The addition of palbociclib significantly prolongs progression-free survival, with a manageable and well-known safety profile.
These results may meaningfully impact first-line maintenance strategies in HR+/HER2+ metastatic breast cancer.
A sincere thank you to all study groups, investigators, and patients who made this important research possible.”
Title: Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Authors: Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Travis Dockter, Xavier Gonzàlez Farré, Prudence A. Francis, Filipa Lynce, Jane Lanzillotti, Carter DuFrane, Anna Wall, Carrie Strand, Ian Krop, Ines Vaz-Luis, Debu Tripathy et al.
Jornal: The New England Journal of Medicine
Read full publication here.
Other OncoDaily articles featuring Sibylle Loibl.